Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
1
|
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.
|
Nat Med
|
2002
|
23.42
|
2
|
The B7 family revisited.
|
Annu Rev Immunol
|
2005
|
13.51
|
3
|
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
|
J Clin Oncol
|
2005
|
12.88
|
4
|
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.
|
Proc Natl Acad Sci U S A
|
2002
|
12.39
|
5
|
Inhibitory B7-family molecules in the tumour microenvironment.
|
Nat Rev Immunol
|
2008
|
8.17
|
6
|
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
|
Lancet
|
2012
|
7.31
|
7
|
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.
|
J Clin Oncol
|
2009
|
7.21
|
8
|
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
|
Lancet Oncol
|
2011
|
7.10
|
9
|
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells.
|
J Exp Med
|
2009
|
6.80
|
10
|
The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
|
J Clin Oncol
|
2003
|
6.57
|
11
|
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
|
J Clin Oncol
|
2008
|
6.31
|
12
|
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms.
|
Mol Cell Biol
|
2005
|
6.18
|
13
|
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.
|
Blood
|
2009
|
6.17
|
14
|
The PD-1 pathway in tolerance and autoimmunity.
|
Immunol Rev
|
2010
|
5.99
|
15
|
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
|
Lancet
|
2010
|
5.79
|
16
|
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells.
|
Cancer Res
|
2004
|
5.59
|
17
|
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.
|
Cancer Res
|
2005
|
4.94
|
18
|
SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation.
|
J Immunol
|
2004
|
4.58
|
19
|
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer.
|
Genome Biol
|
2007
|
4.33
|
20
|
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.
|
Ann Oncol
|
2014
|
4.27
|
21
|
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.
|
Cancer Res
|
2003
|
3.96
|
22
|
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.
|
Ann Oncol
|
2014
|
3.80
|
23
|
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.
|
Neoplasia
|
2006
|
3.54
|
24
|
The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis.
|
Br J Cancer
|
2011
|
3.45
|
25
|
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine.
|
Proc Natl Acad Sci U S A
|
2001
|
3.32
|
26
|
Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel.
|
J Clin Oncol
|
2002
|
3.29
|
27
|
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment.
|
Ann Oncol
|
2010
|
2.94
|
28
|
PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta.
|
FEBS Lett
|
2004
|
2.77
|
29
|
In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas.
|
Clin Cancer Res
|
2014
|
2.68
|
30
|
PD-1 signaling in primary T cells.
|
Immunol Rev
|
2009
|
2.66
|
31
|
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.
|
Breast Cancer Res
|
2009
|
2.26
|
32
|
Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
|
Semin Oncol
|
2010
|
2.24
|
33
|
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
|
N Engl J Med
|
2017
|
2.11
|
34
|
Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.
|
Ann Oncol
|
2014
|
2.10
|
35
|
PD-L1 expression in triple-negative breast cancer.
|
Cancer Immunol Res
|
2014
|
2.06
|
36
|
A gene expression signature identifies two prognostic subgroups of basal breast cancer.
|
Breast Cancer Res Treat
|
2010
|
2.03
|
37
|
Immune regulation of cancer.
|
J Clin Oncol
|
2010
|
1.99
|
38
|
Inflammatory breast cancer: a review.
|
J Clin Oncol
|
1992
|
1.93
|
39
|
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment.
|
J Immunother Cancer
|
2014
|
1.92
|
40
|
Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.
|
Lancet Oncol
|
2012
|
1.91
|
41
|
Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer.
|
Clin Cancer Res
|
2002
|
1.82
|
42
|
Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy.
|
Clin Cancer Res
|
2001
|
1.76
|
43
|
Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992.
|
Cancer
|
1998
|
1.71
|
44
|
Structural and functional analysis of the costimulatory receptor programmed death-1.
|
Immunity
|
2004
|
1.70
|
45
|
In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival.
|
J Pathol
|
2011
|
1.69
|
46
|
FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy.
|
BMC Cancer
|
2008
|
1.63
|
47
|
Prognostic and predictive value of PDL1 expression in breast cancer.
|
Oncotarget
|
2015
|
1.62
|
48
|
Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease.
|
Cancer
|
2007
|
1.56
|
49
|
Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells.
|
Int J Cancer
|
2007
|
1.53
|
50
|
Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis.
|
Br J Cancer
|
2014
|
1.51
|
51
|
PD-L1 expression is increased in a subset of basal type breast cancer cells.
|
PLoS One
|
2014
|
1.46
|
52
|
PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer.
|
Cancer Immunol Res
|
2014
|
1.40
|
53
|
Update on inflammatory breast cancer.
|
Breast Cancer Res
|
2005
|
1.29
|
54
|
Kinome expression profiling and prognosis of basal breast cancers.
|
Mol Cancer
|
2011
|
1.22
|
55
|
Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
|
Ann Oncol
|
2013
|
1.14
|
56
|
B7-H1 expression on non-B and non-T cells promotes distinct effects on T- and B-cell responses in autoimmune arthritis.
|
Eur J Immunol
|
2010
|
1.11
|
57
|
Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy.
|
J Clin Oncol
|
1986
|
1.05
|
58
|
PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy.
|
Oncotarget
|
2015
|
1.04
|
59
|
Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy.
|
Immunotherapy
|
2014
|
1.02
|
60
|
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
|
Lancet Oncol
|
2017
|
0.91
|
61
|
Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience.
|
Clin Breast Cancer
|
2004
|
0.90
|
62
|
UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.
|
Ann Oncol
|
2015
|
0.90
|
63
|
Paclitaxel in the multimodality treatment for inflammatory breast carcinoma.
|
Cancer
|
2001
|
0.90
|
64
|
Tumor-infiltrating lymphocytes and their significance in melanoma prognosis.
|
Methods Mol Biol
|
2014
|
0.86
|
65
|
Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer.
|
Cancer Chemother Pharmacol
|
2004
|
0.84
|
66
|
Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer.
|
Ann Oncol
|
2005
|
0.84
|
67
|
Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer.
|
Anticancer Drugs
|
2005
|
0.81
|
68
|
Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study.
|
Cancer
|
2002
|
0.81
|
69
|
The Centre H. Becquerel studies in inflammatory non metastatic breast cancer. Combined modality approach in 178 patients.
|
Br J Cancer
|
1993
|
0.80
|
70
|
Treatment of inflammatory breast cancer with combination chemotherapy and mastectomy versus breast conservation.
|
Cancer
|
1988
|
0.75
|